Clinical Trials Browser

NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT04671667 2026-05-08

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

188 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03180268 2026-05-07

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Phase 3 Recruiting

163 enrolled

CNS

Meningioma

NCT03801876 2026-05-07

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Phase 3 Recruiting

300 enrolled

Gastrointestinal

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

Clinical Trials

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Phase II Study of Proton Radiation Therapy for Neuroblastoma

Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

HIT-Meso

Retro-Ion

Proton Therapy for Recurrent Nasopharyngeal Carcinoma

Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors

HiPPI

Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

PRIDE

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

COMPRO

Proton Therapy for Esophageal Cancer

PIRATES

PRO-Hodgkin

Protons Vs. Photons for High-risk Prostate Cancer

PROTECT

Proton Therapy for Locally Advanced Cervical Cancer

A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma

PROTHYM